Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

INTRODUCTION:The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). This post hoc analysis of EXIST-2 study aimed to assess angiomy...

Full description

Bibliographic Details
Main Authors: John J Bissler, Norio Nonomura, Klemens Budde, Bernard A Zonnenberg, Michael Fischereder, Maurizio Voi, Anne-Laure Louveau, Fabian Herbst, E Martina Bebin, Paolo Curatolo, Andrea Zonta, Elena Belousova
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6128468?pdf=render

Internet

http://europepmc.org/articles/PMC6128468?pdf=render

Similar Items